Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board. (Triangle Business Journal)
Recent Campus Connections News: